On April 1, 2025, Peijia Medical held a strategic innovation cooperation signing ceremony and press conference at its global headquarters, announcing a collaboration with the biomedical division of DSM-Firmenich, an innovator in nutrition, health, and beauty. The partnership will leverage ultra-high molecular weight polyethylene (UHMWPE) and thermoplastic polyurethane (TPU The high-polymer heart valve developed by R&D has achieved results. The signing of the memorandum of strategic innovation partnership between the two parties will further focus on the R&D and innovation of high-polymer valve materials, which is expected to lead a revolutionary change in the global high-end medical device materials field.

Dr. Yi Zhang, Chairman and CEO of Peijia Medical, signed a strategic innovation cooperation agreement with Paul Spencer, President of the DSM-Firmenich Biomedical Business Unit.

Peijia Medical is a leading company in China's structural heart disease and cerebrovascular介入高端医疗器械领域，拥有覆盖主要瓣膜疾病和下一代核心技术的结构性心脏病产品管线组合和产品开发团队，以及面向出血及缺血性脑卒中市场的完备商业化产品和创新术式组合。2024年沛嘉医疗销售收入6.15亿元人民币，同比增长约40%。 Peijia Medical is a leading company in China's structural heart disease and cerebrovascular intervention high-end medical device sector. It has a comprehensive product pipeline and development team covering major valvular diseases and next-generation core technologies for structural heart disease, as well as a complete suite of commercialized products and innovative procedures targeting hemorrhagic and ischemic stroke markets. In 2024, Peijia Medical's sales revenue was 615 million RMB, representing a year-over-year growth of approximately 40%.

Michelle Ortiz, Vice President of Research and Innovation for DSM-Firmenig Biomedical, introduces her company's biomaterial properties and applications.

The DSM-Firmenich Biomedical business unit is headquartered in Pennsylvania, USA, and has an office and innovation application research center in Shanghai, China. As part of the DSM-Firmenich Group, the biomedical division possesses unparalleled expertise in the field of biomaterials and their applications, helping partners like TAE Medical create breakthrough innovations for patients worldwide.

In this collaboration, Peijia Medical and DSM-Firmenich's biomedical business unit have joined forces to achieve new breakthroughs in the research and development of ultra-high molecular weight polyethylene and thermoplastic polyurethane (TPU) valve materials. According to the memorandum, both parties will establish a long-term, stable, and mutually beneficial strategic innovation partnership. Utilizing DSM-Firmenich's biomaterials, the R&D teams from both sides will collaborate on the design and development of new high-end medical device products, performance optimization of key raw materials based on ultra-high molecular weight polyethylene materials, new material development, as well as the development and application of advanced manufacturing processes and technologies.

National Health Commission expert group industry expert Jiang Tianjiao presented a report titled "Cardiac Valve Industry: Evolution of Technical Pathways and Future Trend Outlook."

Ultra-high molecular weight polyethylene fiber is a lightweight and high-strength polymer material, with a strength 15 times that of steel structures of the same size. Using ultrafine fibers and employing unique weaving and multi-layer fusion technology, a polymer valve material is produced that can perfectly replace existing animal-derived heart valve materials. This product offers significant potential for improvement in flexibility and biocompatibility, promising a revolutionary upgrade in valve materials.

Polymer valve materials are non-biological, inorganic materials with significant advantages in physical and biochemical properties, as well as lifespan, making them suitable for younger patients. Compared to traditional animal-derived valve materials, polymer valve materials have two major advantages: on one hand, they enhance product lifespan and expand indications; on the other hand, they reduce costs and are suitable for mass production. This is of great significance for the development of the heart valve market, benefiting a larger patient population.

Peijia Medical's Chief Operating Officer Pan Kongrong introduced the progress of the Peijia polymer valve project and animal experiment data.

The polymer valve independently developed by Peijia Medical is a new type of polymer valve that uses a five-layer bionic polymer fiber woven material as the valve material, simulating the functions of the corresponding layers of materials in the human autologous valve leaflets, making it closer to the functions of human autologous valves. This product has maintained stable hemodynamics after 400 million accelerated fatigue tests, demonstrating outstanding durability, with an expected lifespan far exceeding that of current biological valve materials. The development of this product has successfully been included in Suzhou's key core technology tackling project aimed at global challenges. Currently, the product has completed animal experiments and is preparing to enter clinical trials.

Peijia Medical's Chief Operating Officer, Kanger Pan, stated that based on years of collaboration with DSM-Resins & Functional Materials, the two parties will now enter into a deeper level of synergy. The development of high molecular weight valve material, as a core platform technology for Peijia Medical, will, once developed, be applied across various product lines to enhance their performance and open up applications of ultra-high molecular weight polyethylene in the field of structural heart disease.

Paul Spencer, President of DSM-Firmenich's Biomedical Division, stated, "At DSM-Firmenich, we are committed to advancing the development of vascular applications through innovative biomaterial solutions, supporting the goals of achieving better clinical outcomes, reducing healthcare costs, and improving the lives of patients worldwide. We are very pleased to officially collaborate with Peijia to jointly promote this vision in China."